Home > News > Altair Nanotechnologies Testing RenaZorb With 2nd Pharm. Co.
January 27th, 2003
Altair Nanotechnologies Testing RenaZorb With 2nd Pharm. Co.
Altair Nanotechnologies Inc. (Nasdaq:ALTI) announced that it has entered into a testing agreement with a second pharmaceutical company for in vivo (animal) evaluation of RenaZorb(TM), its new pharmaceutical candidate for phosphate control in kidney dialysis patients.
Novel stapled peptide nanoparticle combination prevents RSV infection, study finds April 17th, 2014
More effective kidney stone treatment, from the macroscopic to the nanoscale April 17th, 2014
High-temperature plasmonics eyed for solar, computer innovation April 17th, 2014
Harris & Harris Group Continues Its Blog Series to Highlight Most Impactful Portfolio Companies With Champions Oncology, Inc. April 17th, 2014